1. “Cranky Old Guard.” Who exactly is blocking progress

Halle talks about the “Cranky Old Guard” (COG). And the obvious question is. Are we talking about a small group of villains, or basically the whole industry.

Because sometimes it feels like everyone is the “Cranky Old Guard.” From VCs to incumbent lobbyists to vendors protecting their margins.

I asked Halle to define it plainly and explain how innovators deal with it without becoming it.

2. What smart outsiders consistently get wrong

People love to blame insurance and PBMs, and yes, that is part of the crisis. But the deeper issue is incentive alignment.

We pressed on what innovative outsiders misunderstand when they first enter healthcare, and why so many “obvious” fixes die on contact with reality.

If you are building in this space, this part is not philosophy. It is survival.

3. The ACA. What critique is worth taking seriously

The Affordable Care Act moved real needles, including coverage expansion and protections for preexisting conditions. That is not controversial if you can read data.

But it is also under political crossfire from both sides.

So I asked a question that is rare in health tech circles. What is the strongest critique of the ACA that Halle actually takes seriously.

You do not improve systems by treating them like sacred objects. You improve systems by being honest about where they fail.

4. Drug prices, NIH, and the uncomfortable “societal investment” argument

Halle’s book cites the reality that U.S. drug prices are dramatically higher than elsewhere, and that taxpayers often support upstream science through NIH-funded research.

We also brought up biotech investor Peter Kolchinsky’s argument that expensive branded drugs should be viewed as a societal investment rather than an expense, and asked whether Halle buys it.

This is one of those debates where smart people can disagree in good faith, and still be forced to confront a nasty truth. Our current structure makes it too easy to extract value without creating proportional public benefit.

5. Interoperability. Is it really “vendors not willing”

I pushed back here as someone who actually works with providers and lives inside the constraints.

If you have spent more than 20 minutes trying to integrate into a health system, you already know the fairy tale version of interoperability. “If everyone would just cooperate, data would flow.”

But the hard version is economics. Incumbent EHRs sit on a wildly profitable status quo. Breaking that status quo is not a technical problem. It is a business model problem.

So I challenged the framing directly.

6. Screens, anxiety, and the dirty secret of “helpful” tools

Halle has talked publicly about minimizing exposure to social media and doing a “mobile device detox.”

I connected that to a broader, uncomfortable question in digital health. What if some tools make people more anxious rather than healthier.

I referenced a point raised by Dr. Ezekiel Emanuel about gadgets like the Oura ring. If you wake up refreshed, you already have signal. If the device adds anxiety and does not add therapy, what are we really selling?

Then I asked the question all founders hate: Does minimizing screen time also mean minimizing screen time for digital health tools?

7. Transparency. Why everyone whispers and nobody names failure modes

Healthcare is political. Digital health is small. People network. People fund each other. People want future deals.

Which means almost nobody calls out bad actors or even names real failure modes, because nobody wants to burn bridges.

So I asked. How do we change that?

If you care about credibility in this industry, this is not optional. It is the whole game.

8. Women’s health, women investing, and a message to my daughters

This one is personal.

I brought up my daughters, the reality of inequality in women’s health and in the workplace, and the need for role models who do not just win. Role models who do the right thing with their voice.

I asked Halle what message she would give to them, and whether there is hope.